TCT 265: GDF-15 as an early marker for prognosis in patients with cardiogenic shock – Experience from the HAnnover Cardiac Unloading REgistry (HACURE)

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abiomed; Amgen; AstraZenca; Daiichi-Sankyo/Elil Lilly and Company; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Zoll</li><li>Grant Support/Research Contract - Abiomed; Daiichi-Sankyo/Elil Lilly and Company</li></ul>